Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140712 · ClinicalTrials.gov registry record · Phase 1
Ropinirole Tablets In Young Patients With Restless Legs Syndrome
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00140712 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 9 participants.
The verdict
NCT00140712, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a two-period dose rising study of Ropinirole Immediate Release in adolescent patients with restless legs syndrome (RLS) in order to determine the starting dose for the ropinirole titration regimen for this age group. Patients will receive two single doses unless poor tolerability is observed following the first dose.
Interventions
- DRUG Ropinirole Immediate Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2005-06-10 |
| Est. Completion | 2008-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140712
The ClinicalTrials.gov registry entry for NCT00140712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropinirole Immediate Release is the first listed.
NCT00140712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140712 about?
NCT00140712 is a clinical study titled "Ropinirole Tablets In Young Patients With Restless Legs Syndrome". This is a two-period dose rising study of Ropinirole Immediate Release in adolescent patients with restless legs syndrome (RLS) in order to determine the starting dose for the ropinirole titration regimen for this age group. Patients will receive two single doses unless poor tolerability is observed...
What is the current status of trial NCT00140712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2005-06-10. Estimated completion is 2008-02-28.
What interventions are being tested in trial NCT00140712?
The interventions under investigation include: Ropinirole Immediate Release (DRUG).
Who is sponsoring clinical trial NCT00140712?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.